Metastatic triple-negative breast carcinoma
Clinical trials for Metastatic triple-negative breast carcinoma explained in plain language.
Never miss a new study
Get alerted when new Metastatic triple-negative breast carcinoma trials appear
Sign up with your email to follow new studies for Metastatic triple-negative breast carcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a drug cocktail make immunotherapy work better for Hard-to-Treat breast cancer?
Disease control Stopped earlyThis early-phase trial tests whether adding a combination of rintatolimod, celecoxib, and interferon alpha-2b can enhance the effectiveness of pembrolizumab, an immunotherapy drug, in people with metastatic or unresectable triple-negative breast cancer. The combination aims to mo…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase 1/2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug combo targets brain metastases in advanced cancers
Disease control Stopped earlyThis study tested a combination of two drugs, bintrafusp alfa and pimasertib, in people whose cancer had spread to the brain. The goal was to find the safest dose and see if the treatment could slow or stop the cancer from growing. The trial was stopped early after enrolling only…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New cocktail of drugs tested for Hard-to-Treat breast cancer – but trial halted early
Disease control Stopped earlyThis phase II study tested several drug combinations for people with metastatic triple-negative breast cancer, a type that has spread and lacks common hormone targets. The drugs included olaparib (a PARP inhibitor) paired with either durvalumab (an immunotherapy), selumetinib, ca…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase 2 • Sponsor: Gordon Mills, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New Full-Body scan could replace biopsies for breast cancer immunotherapy
Diagnosis Stopped earlyThis study tested a special PET/CT scan that uses a radioactive tracer to see PD-L1 (a protein targeted by immunotherapy) throughout the body. The goal was to see if this scan could better identify which patients with metastatic triple-negative breast cancer would benefit from im…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Sponsor: Karolinska University Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 11:00 UTC